Guildford, UK, 27 November 2009: ReNeuron Group plc (LSE: RENE.L) announces that it has been awarded two grants under the Government-backed Technology Strategy Board’s Regenerative Medicine Programme. This funding programme was launched earlier this year to underpin and enable the best regenerative medicine businesses to flourish in the UK.
Guildford, UK, 26 November 2009: ReNeuron Group plc (LSE: RENE.L; “the Company”) announces that it has secured a two-year equity funding facility up to £5 million from Matrix Corporate Capital LLP (“Matrix”), the Company’s joint broker.
ReNeuron announces its interim results for the period ending 30th September 2009. Full details can be downloaded from the Company’s website at www.reneuron.com
Guildford, UK, 23 November 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its interim results for the six months ending 30 September 2009 on Thursday 26 November 2009. A conference call for analysts will be held at 9.30 GMT on that day. For further information, please contact Juliet Edwards on the number below.
Guildford, UK, 16 November 2009: ReNeuron Group plc (LSE: RENE.L) announces further positive pre-clinical efficacy data with its ReN009 stem cell therapy for peripheral arterial disease (PAD). PAD is a chronic and debilitating disease that progressively restricts blood flow in the limbs, causing cramping, chronic pain and in extreme cases, loss of limb. PAD is commonly associated with other conditions such as diabetes, obesity and stroke. At least 1 in 20 people over the age of 55 have some degree of PAD and it becomes more common with increasing age.
Guildford, UK, 22 October 2009: ReNeuron Group plc (LSE: RENE.L) announces that it will present its approach to the treatment of disabled stroke patients with its ReN001 stem cell therapy at the Royal Society of Medicine’s 10th Medical Innovations Briefing to be held in London on the evening of 27 October 2009.
Guildford, UK, 2 October 2009: ReNeuron Group plc (LSE: RENE.L) announces the recent publication of new research using its ReNcell® neural stem cell products. These human cell lines and supporting products are marketed through US-based Millipore Corporation for academic and commercial research.
Guildford, UK, 17 September 2009: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today’s 2009 Annual General Meeting were passed.
Guildford, UK, 17 September 2009: ReNeuron Group plc (LSE: RENE) today announces a business update ahead of its 2009 Annual General Meeting.
ReN001 stem cell therapy for stroke
In July, the Company announced that the UK Gene Therapy Advisory Committee (GTAC) had issued a final ethical opinion, subject to certain conditions, in favour of ReNeuron’s proposed first-in-man clinical trial with ReN001, its stem cell therapy for stroke.
